54
|
Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, Van Quaquebeke E, Kiss R. Structure−Activity Relationship Analysis of Novel Derivatives of Narciclasine (an Amaryllidaceae Isocarbostyril Derivative) as Potential Anticancer Agents. J Med Chem 2009; 52:1100-14. [DOI: 10.1021/jm8013585] [Citation(s) in RCA: 117] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Laurent Ingrassia
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Florence Lefranc
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Janique Dewelle
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Laurent Pottier
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Véronique Mathieu
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Sabine Spiegl-Kreinecker
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Sébastien Sauvage
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Mohamed El Yazidi
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Mischaël Dehoux
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Walter Berger
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Eric Van Quaquebeke
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| | - Robert Kiss
- Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium, Service de Neurochirurgie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, CP205/1, Boulevard du Triomphe, 1050 Brussels, Belgium, Department of Neurosurgery, Wagner Jauregg Hospital, Linz, Austria, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
| |
Collapse
|
57
|
Kabbage M, Chahed K, Hamrita B, Guillier CL, Trimeche M, Remadi S, Hoebeke J, Chouchane L. Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol 2008; 2008:564127. [PMID: 18401453 PMCID: PMC2288682 DOI: 10.1155/2008/564127] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2007] [Revised: 11/20/2007] [Accepted: 01/19/2008] [Indexed: 01/03/2023] Open
Abstract
Improvement of breast-cancer detection through the identification of potential cancer biomarkers is considered as a promising strategy for effective assessment of the disease. The current study has used nonequilibrium pH gradient electrophoresis with subsequent analysis by mass spectrometry to identify protein alterations in invasive ductal carcinomas of the breast from Tunisian women. We have identified multiple protein alterations in tumor tissues that were picked, processed, and unambiguously assigned identities by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF). The proteins identified span a wide range of functions and are believed to have potential clinical applications as cancer biomarkers. They include glycolytic enzymes, molecular chaperones, cytoskeletal-related proteins, antioxydant enzymes, and immunologic related proteins. Among these proteins, enolase 1, phosphoglycerate kinase 1, deoxyhemoglobin, Mn-superoxyde dismutase, alpha-B-crystallin, HSP27, Raf kinase inhibitor protein, heterogeneous nuclear ribonucleoprotein A2/B1, cofilin 1, and peptidylprolyl isomerase A were overexpressed in tumors compared with normal tissues. In contrast, the IGHG1 protein, the complement C3 component C3c, which are two newly identified protein markers, were downregulated in IDCA tissues.
Collapse
Affiliation(s)
- Maria Kabbage
- Laboratoire d'Immuno-Oncologie Moléculaire,
Faculté de Médecine de Monastir,
5019 Monastir,
Tunisia
| | - Karim Chahed
- Laboratoire d'Immuno-Oncologie Moléculaire,
Faculté de Médecine de Monastir,
5019 Monastir,
Tunisia
- Institut Supérieur de Biotechnologie de Monastir,
5000 Monastir,
Tunisia
| | - Bechr Hamrita
- Laboratoire d'Immuno-Oncologie Moléculaire,
Faculté de Médecine de Monastir,
5019 Monastir,
Tunisia
| | | | - Mounir Trimeche
- Departement de Pathologie,
Centre Hospitalo-Universitaire Farhat-Hached,
4002 Sousse,
Tunisia
| | | | - Johan Hoebeke
- Immunologie et Chimie th_rapeutiques,
UPR 9021-CNRS,
Institut de Biologie Moléculaire et Cellulaire,
67084 Strasbourg,
France
| | - Lotfi Chouchane
- Department of Genetic Medicine,
Weill Cornell Medical College in Qatar, and Qatar Foundation,
Doha,
Qatar
| |
Collapse
|